News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synta Pharmaceuticals (SNTA) Announces Upcoming Presentations at the 15th World Conference on Lung Cancer


10/23/2013 7:22:01 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results from the GALAXY-1 trial, which evaluates the Company’s lead drug candidate ganetespib in patients with advanced non-small cell lung adenocarcinoma, will be presented during an oral session at the 15th World Conference on Lung Cancer (WCLC) in Sydney, Australia:

“Randomized Phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES